UPP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16561913	1.00	5/20
SCHEMBL16561915	1.00	5/20
SCHEMBL16561918	1.00	5/20
SCHEMBL9114390	0.80	5/20
SCHEMBL16561956	0.74	5/20
SCHEMBL16561957	0.72	5/20
SCHEMBL11121714	0.69	5/20
SCHEMBL6655303	0.68	5/20
SCHEMBL6625526	0.66	5/20
SCHEMBL5182348	0.64	5/20
SCHEMBL8025123	0.64	5/20
SCHEMBL8901518	0.61	5/20
SCHEMBL9114384	0.60	5/20
SCHEMBL11051571	0.56	5/20
SCHEMBL11493834	0.55	5/20
SCHEMBL11239998	0.55	5/20
SCHEMBL1086023	0.53	5/20
SCHEMBL11496948	0.53	5/20
SCHEMBL11131319	0.52	5/20
SCHEMBL26354493	0.51	5/20

Clinical trials — most relevant to UPP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)	PHASE3	COMPLETED
Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer	PHASE2	UNKNOWN
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients	PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	PHASE2	COMPLETED
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer	PHASE2	COMPLETED
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
PRO#0118: Decitabine Plus Mini Flu-Bu	PHASE1	COMPLETED
Phosphoproteomic Profile of Children With Down Syndrome	nan	COMPLETED
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Neurologic Injuries in Adults With Urea Cycle Disorders	nan	COMPLETED
Genetics and Epidemiology of Aging Associated Conditions in the Sardinian Population	nan	COMPLETED
Improving the Safety of Fluoropyrimidine-based Chemotherapy	nan	UNKNOWN
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network	nan	RECRUITING
The Nosology and Etiology of Leukodystrophies of Unknown Causes	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Digestive Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy	nan	UNKNOWN
The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Stakeholders of Rare Diseases Informing Values In Neuroethics	nan	RECRUITING
An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a UPP1 binder may also engage these)

Protein	Name	Similarity
P52624	—	1.000	P52624 →
Q8CGR7	—	0.982	Q8CGR7 →
O95045	—	0.972	O95045 →
Q8R3P0	—	0.965	Q8R3P0 →
A8KB34	—	0.963	A8KB34 →
Q9R1T5	—	0.963	Q9R1T5 →
Q9EQR2	—	0.962	Q9EQR2 →
B4G0F3	—	0.961	B4G0F3 →
P31754	—	0.961	P31754 →
Q8BMF3	—	0.960	Q8BMF3 →
AGPS	Alkyldihydroxyacetonephosphate synthase, peroxisomal	0.960	landscape →
Q9CYR6	—	0.960	Q9CYR6 →
P45381	—	0.960	P45381 →
O95394	—	0.960	O95394 →
Q3TMV7	—	0.960	Q3TMV7 →
ME3	NADP-dependent malic enzyme, mitochondrial	0.960	landscape →
P28227	—	0.960	P28227 →
Q8C0I1	—	0.959	Q8C0I1 →
B1PK17	—	0.959	B1PK17 →
P70712	—	0.959	P70712 →
Q291H4	—	0.959	Q291H4 →
P97275	—	0.958	P97275 →
A7M6E8	—	0.958	A7M6E8 →
P46446	—	0.958	P46446 →
A9RBS1	—	0.958	A9RBS1 →
P31254	—	0.957	P31254 →
P40927	—	0.957	P40927 →
Q8CIG8	—	0.957	Q8CIG8 →
PRMT5	Protein arginine N-methyltransferase 5	0.957	landscape →
A1L258	—	0.957	A1L258 →